DS-8201a: Preliminary Phase I data

Preliminary data from 20 evaluable patients with advanced solid tumors in the dose-escalation part of an open-label, U.S. and Japanese Phase I trial showed that 0.8-8 mg/kg doses of IV DS-8201a every ...